Biotech News

Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

Vaxcyte (PCVX)Vaxcyte2026-04-07 20:05 ESTConference / presentation

SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 2:15

Related news

PCVXVaxcyte2026-03-18 23:34 EST

Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

PCVXVaxcyte2026-03-23 12:30 EST

Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

VXRTVaxart2026-02-18 13:00 EST

Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026

GSKGSK plc2026-01-07 12:00 EST

GSK’s Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved by the European Commission

GOVXGeoVax Labs2024-11-26 14:00 EST

GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference

VXRTVaxart2026-07-21 12:00 EST

Vaxart to Participate in BTIG Biotechnology Conference 2026

GSKGSK plc2025-10-21 07:05 EST

GSK’s Shingrix new prefilled syringe presentation receives positive CHMP opinion

View all latest news

Vaxcyte

Carrier-Sparing Vaccine Platform Vaxcyte develops broad-spectrum conjugate vaccines using a platform designed to include more bacterial antigens without overloading the carrier proteins needed to generate immune responses. Adult VAX-31 Program VAX-31 is a 31-valent pneumococcal conjugate vaccine in Phase 3 development for adults. The...

Recent company news

PCVXVaxcyte2026-08-05 20:05 EST

Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update

PCVXVaxcyte2026-07-08 20:05 EST

Vaxcyte to Participate in Upcoming Investor Conferences

PCVXVaxcyte2026-06-02 20:05 EST

Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults

PCVXVaxcyte2026-05-06 20:05 EST

Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update

PCVXVaxcyte2026-04-07 20:05 EST

Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference

Stock data

Close: 58.89 USD
Market cap: 6.85B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States